Willow Biosciences and Kalsec announced the advancement of their functional ingredient development program for a large volume savory foods opportunity. Following the completion of phase one that applied BioOxi, Kalsec has agreed to continue full development toward commercialization, which will include R&D and scale-up work. "We appreciate the trust Kalsec has in Willow to help with our innovation pathway and are delighted to partner with them on this next step in our engagement on ingredient development," said Dr. Chris Savile, Willow President & CEO. "Looking forward, we are excited by the opportunity to engage with Kalsec’s extraordinary team in bringing to market what could potentially be a number of sustainably sourced innovative ingredients that favorably enhance customers' products and the consumer experience."
MAHA: Implications for FDA Reform, State Regulations, and More
December 17, 2024
